Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited

@article{Paumgartner2002UrsodeoxycholicAI,
  title={Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited},
  author={G. Paumgartner and U. Beuers},
  journal={Hepatology},
  year={2002},
  volume={36}
}
Ursodeoxycholic acid (UCDA) is increasingly used for the treatment of cholestatic liver diseases. Experimental evidence suggests three major mechanisms of action: (1) protection of cholangiocytes against cytotoxicity of hydrophobic bile acids, resulting from modulation of the composition of mixed phospholipid‐rich micelles, reduction of bile acid cytotoxicity of bile and, possibly, decrease of the concentration of hydrophobic bile acids in the cholangiocytes; (2) stimulation of hepatobiliary… Expand
Ursodeoxycholic acid for primary biliary cirrhosis: treat early to slow progression.
TLDR
Additional trials with longer duration and sufficient dosage of UDCA would be desirable, but are difficult to perform since on the basis of available evidence UDCA therapy has been recommended in the guide lines of large medical associations such as the American Association for the Study of Liver Diseases. Expand
Ursodeoxycholic Acid for the Treatment of Liver Diseases
TLDR
Ursodeoxycholic acid is considered as the first-line treatment for primary biliary cirrhosis and intrahepatic cholestasis of pregnancy without side effect to babies and there is insufficient evidence either to support or to refute effects on long-term outcomes in noncholestatic liver diseases. Expand
The Therapeutic Role of Ursodeoxycholic Acid in Digestive Diseases
TLDR
Several potential uses of UDCA warrant further investigation after initial studies have shown promise including treatment for microlithiasis, intrahepatic cholestasis of pregnancy, total parenteral nutrition, chemoprophylaxis of colorectal cancer in patients with ulcerative colitis and PSC, viral hepatitis, and in bone marrow transplantation. Expand
Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease.
TLDR
Through one or more of these mechanisms, UDCA slows the progression of primary biliary cirrhosis and improves a number of other cholestatic disorders. Expand
Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health.
TLDR
Taurine conjugation may represent an adaptive mechanism in PBC against chenodeoxycholic acid-mediated bile duct damage and stabilize small intestinal detoxification by upregulation of efflux pumps. Expand
Immunomodulating and anti-apoptotic action of ursodeoxycholic acid: where are we and where should we go?
  • S. Bellentani
  • Medicine
  • European journal of gastroenterology & hepatology
  • 2005
TLDR
In this issue of the journal, Weitzel and co-workers clearly demonstrated that the binding of UDCA to the glucocorticoid receptor is unspecific, and the anti-inflammatory, cytoprotective and anti-apoptotic actions ofUDCA should be due not only to the mild interaction with the glucose receptor, but also to transactivation or transrepression of different cytoplasmic proteins that are involved in the survival pathway. Expand
Defective canalicular transport and toxicity of dietary ursodeoxycholic acid in the abcb11-/- mouse: transport and gene expression studies.
  • Renxue Wang, L. Liu, +4 authors V. Ling
  • Chemistry, Medicine
  • American journal of physiology. Gastrointestinal and liver physiology
  • 2013
TLDR
It was concluded that infusion of UDCA and TUDC failed to induce bile flow in abcb11-/- mice, and Semiquantitative RT-PCR showed that genes encoding Mdr 1a and Mdr1b (canalicular) as well as Mrp4 (basolateral) transporters were upregulated in abCB11- +/- mice. Expand
Ursodeoxycholic acid stimulates the formation of the bile canalicular network.
TLDR
The data provide new evidence of the pharmacological potential of UDCA in accelerating or regenerating BC network formation in vitro, in hepatic cell culture models, and in vivo in a rat model of hepatic injury, and provide a basis for understanding its hepatoprotective effects. Expand
Ursodeoxycholic acid in cholestatic liver diseases : current status
  • 2011
Ursodeoxycholic acid (UDCA) is the most hydrophilic and almost nontoxic bile acid with multiple mechanisms of action, including choleretic, cytoprotective (for both, hepatocytes and cholangiocytes),Expand
Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets.
TLDR
The clinical results of ursodeoxcholic acid therapy of primary biliary cirrhosis may be regarded as the first success of this strategy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 57 REFERENCES
Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver.
TLDR
Down-regulation of basolateral and up- regulation of canalicular transporters in response to CA may represent a defense mechanism, in an attempt to prevent hepatocellular accumulation of potentially toxic bile acids. Expand
Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.
TLDR
In PBC and PSC, there is a defect in hepatic bile acids excretion but not in uptake, implying bile acid retention, which is reduced by UDCA. Expand
Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene.
TLDR
The cholangiolitis and its sequelae in the mdr2 knockout mice depend on bile salt hydrophobicity. Expand
Ursodeoxycholic Acid May Inhibit Deoxycholic Acid-Induced Apoptosis by Modulating Mitochondrial Transmembrane Potential and Reactive Oxygen Species Production
TLDR
UDCA significantly reduces DCA-induced disruption of ΔΨm, ROS production, and Bax protein abundance in mitochondria, suggesting both short- and long-term mechanisms in preventing MPT. Expand
Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes.
TLDR
It seems likely that in severe cholestatic liver disease, bile-acid-induced injury of hepatocytes is due mainly to cytolysis, whereas in moderately severeCholestasis apoptosis represents the predominant mechanism of bile acid toxicity. Expand
Pharmacology of ursodeoxycholic acid, an enterohepatic drug.
  • A. Hofmann
  • Chemistry, Medicine
  • Scandinavian journal of gastroenterology. Supplement
  • 1994
TLDR
Ursodeoxycholic acid is a choleretic agent, as all bile acids, but differs from other dihydroxy-bile acids in being non-cytotoxic because it has less affinity for membranes, and when present at micellar concentrations does not solubilize membranes. Expand
Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha
TLDR
In conclusion, activation of Ca2+‐dependent PKC alpha is required for UDCA and TUDCA inhibition of cholangiocyte growth and secretion. Expand
Ursodeoxycholic acid in cholestasis: Potential mechanisms of action and therapeutic applications
TLDR
Clinical and experimental work that may help to clarify possible mechanisms of action of UDCA in cholestasis and provide a clearer rationale for the administration ofUDCA in special cholESTatic disorders are summarized. Expand
Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes.
TLDR
TUDCA might stimulate Ca(2+)-dependent hepatocellular exocytosis into bile in part by activation of alpha-PKC. Expand
Tauroursodesoxycholate-induced choleresis involves p38(MAPK) activation and translocation of the bile salt export pump in rats.
TLDR
TUDC-induced stimulation of canalicular TC excretion involves a MAP kinase-dependent translocation of subcanalicular Bsep to the canalicular membrane and dual activation of Erks and p38(MAPK) is required for the choleretic effect of both TUDC and hypo-osmotic cell swelling. Expand
...
1
2
3
4
5
...